Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACHV 
Achieve Life Sciences Inc (ACHV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: ACHV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.89
1 Year Target Price $15.89
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.69% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 242.21M USD | Price to earnings Ratio - | 1Y Target Price 15.89 |
Price to earnings Ratio - | 1Y Target Price 15.89 | ||
Volume (30-day avg) 8 | Beta 1.69 | 52 Weeks Range 1.84 - 5.78 | Updated Date 12/3/2025 |
52 Weeks Range 1.84 - 5.78 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.244 | Actual -0.28 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -65.45% | Return on Equity (TTM) -161.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 209382044 | Price to Sales(TTM) - |
Enterprise Value 209382044 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 53233988 | Shares Floating 47162652 |
Shares Outstanding 53233988 | Shares Floating 47162652 | ||
Percent Insiders 4.29 | Percent Institutions 40.7 |
Upturn AI SWOT
Achieve Life Sciences Inc
Company Overview
History and Background
Achieve Life Sciences Inc. is a pharmaceutical company focused on developing and commercializing cytisine for smoking cessation. The company's primary focus is on its proprietary cytisine-based product candidate, cytisinicline, which is being developed as a treatment for nicotine addiction. Founded in 2005, the company has focused on clinical development programs and regulatory submissions.
Core Business Areas
- Pharmaceutical Development: Developing and commercializing cytisinicline for smoking cessation. This includes clinical trials, regulatory approvals, and eventual marketing and sales.
Leadership and Structure
The leadership team consists of a CEO, CFO, and other key executives overseeing clinical development, regulatory affairs, and commercial strategy. The organizational structure is typical of a small pharmaceutical company focused on clinical development.
Top Products and Market Share
Key Offerings
- Cytisinicline: Cytisinicline is Achieve Life Sciences' primary product candidate, a plant-based alkaloid with a high binding affinity to the u03b14u03b22 nicotinic acetylcholine receptor. Cytisinicline is currently undergoing late-stage clinical trials for smoking cessation. Achieve Life Sciences hopes to gain market share from competitors such as Pfizer (CHANTIX) and Johnson & Johnson (Nicorette).
Market Dynamics
Industry Overview
The smoking cessation market is driven by public health initiatives, increased awareness of the health risks of smoking, and the availability of pharmacological and behavioral treatments. The market is competitive, with several established pharmaceutical companies offering nicotine replacement therapies and prescription medications.
Positioning
Achieve Life Sciences is positioning cytisinicline as a novel, effective, and well-tolerated treatment for nicotine addiction, potentially offering a competitive advantage over existing therapies due to its different mechanism of action and potentially better tolerability profile. However, the company must successfully complete regulatory approval to compete.
Total Addressable Market (TAM)
The global smoking cessation market is estimated to be worth billions of USD annually. Achieve Life Sciences aims to capture a portion of this market by offering a new treatment option. Cytisinicline is targeted at smokers who are seeking cessation support, representing a significant TAM.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action of cytisinicline
- Potentially better tolerability profile compared to existing treatments
- Focused pipeline with clear clinical development pathway
Weaknesses
- Single product pipeline
- Reliance on clinical trial success
- Limited commercial infrastructure
- Dependence on external funding
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies for commercialization
- Expansion into other nicotine addiction markets, such as e-cigarettes
- Increased public awareness of the benefits of smoking cessation
Threats
- Failure to achieve positive clinical trial results
- Regulatory hurdles and delays
- Competition from established smoking cessation therapies
- Generic entry if cytisinicline is not adequately protected
Competitors and Market Share
Key Competitors
- PFE
- JNJ
- NVS
Competitive Landscape
Achieve Life Sciences' competitive advantage hinges on the success of cytisinicline. If approved, the drug will compete with existing nicotine replacement therapies (NRTs) and prescription medications. Achieve will need to demonstrate cytisinicline is safer, more effective, or more convenient for smokers to make them switch.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on advancing cytisinicline through clinical trials.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval of cytisinicline. Analyst estimates vary but generally project significant revenue growth if the drug is approved.
Recent Initiatives: Recent initiatives include the ongoing Phase 3 clinical trials of cytisinicline, and active engagement with regulatory agencies like the FDA.
Summary
Achieve Life Sciences is a development-stage pharmaceutical company focusing on cytisinicline for smoking cessation. The company's success depends heavily on the clinical trial results and regulatory approval of its lead candidate. It has a novel mechanism of action, but it also has a single-product pipeline. If approved, it could benefit from significant market opportunities, but they face competition from established players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports, industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and competitor information are subject to change. Investment decisions should be made based on individual risk tolerance and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Achieve Life Sciences Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 1995-10-13 | CEO & Executive Director Dr. Richard A. B. Stewart | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | |
Full time employees 25 | |||
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.